Experiences with new generation vaccines against equine viral arteritis, West Nile disease and African horse sickness (Q36724242)

15 August 2017

1 reference

title

Experiences with new generation vaccines against equine viral arteritis, West Nile disease and African horse sickness (English)

1 reference

15 August 2017

0 references

equine viral arteritis

1 reference

N James MacLachlan

1

1 reference

15 August 2017

Udeni B Balasuriya

2

1 reference

15 August 2017

Nancy L Davis

3

1 reference

15 August 2017

Martha Collier

4

1 reference

15 August 2017

Robert E Johnston

5

1 reference

15 August 2017

Gregory L Ferraro

6

1 reference

15 August 2017

Alan J Guthrie

7

1 reference

15 August 2017

language of work or name

English

0 references

publication date

16 January 2007

1 reference

15 August 2017

1 reference

15 August 2017

25

1 reference

15 August 2017

30

1 reference

15 August 2017

5577-5582

1 reference

Equine viral vaccines: the past, present and future

15 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.058

Gene-based vaccines: recent technical and clinical advances

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.058

Factors influencing the international spread of equine diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.058

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.058

Immune responses to commercial equine vaccines against equine herpesvirus-1, equine influenza virus, eastern equine encephalomyelitis, and tetanus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.058

Serological method using recombinant S2 protein to differentiate equine infectious anemia virus (EIAV)-infected and EIAV-vaccinated horses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.058

Analysis of yearly changes in levels of antibodies to Japanese encephalitis virus nonstructural 1 protein in racehorses in central Japan shows high levels of natural virus activity still exist

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.058

Description of the outbreak of equine influenza (H3N8) in the United Kingdom in 2003, during which recently vaccinated horses in Newmarket developed respiratory disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.058

Vaccination against equine influenza: quid novi?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.058

Antibody and IFN-gamma responses induced by a recombinant canarypox vaccine and challenge infection with equine influenza virus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.058

Comparison of the efficacy of inactivated combination and modified-live virus vaccines against challenge infection with neuropathogenic equine herpesvirus type 1 (EHV-1).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.058

Use of DNA and recombinant canarypox viral (ALVAC) vectors for equine herpes virus vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.058

7 January 2021

Equine viral arteritis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.058

Equine arteritis virus: a review of clinical features and management aspects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.058

Lateral transmission of equine arteritis virus among Lipizzaner stallions in South Africa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.058

The molecular biology of arteriviruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.058

Heterodimerization of the two major envelope proteins is essential for arterivirus infectivity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.058

The immune response to equine arteritis virus: potential lessons for other arteriviruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.058

Differentiation of strains of equine arteritis virus of differing virulence to horses by growth in equine endothelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.058

Generation of a candidate live marker vaccine for equine arteritis virus by deletion of the major virus neutralization domain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.058

Development and evaluation of ELISA procedures to detect antibodies against the major envelope protein (G(L)) of equine arteritis virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.058

Large envelope glycoprotein and nucleocapsid protein of equine arteritis virus (EAV) induce an immune response in Balb/c mice by DNA vaccination; strategy for developing a DNA-vaccine against EAV-infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.058

Stable and long-lasting immune response in horses after DNA vaccination against equine arteritis virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.058

Expression of the two major envelope proteins of equine arteritis virus as a heterodimer is necessary for induction of neutralizing antibodies in mice immunized with recombinant Venezuelan equine encephalitis virus replicon particles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.058

Alphavirus replicon particles expressing the two major envelope proteins of equine arteritis virus induce high level protection against challenge with virulent virus in vaccinated horses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.058

West Nile virus infection of horses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.058

West Nile virus: epidemiology and ecology in North America

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.058

West Nile Virus: A Reemerging Global Pathogen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.058

West Nile virus Epidemic in Horses, Tuscany Region, Italy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.058

Clinical and neuropathological features of West Nile virus equine encephalomyelitis in Italy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.058

West Nile Virus Outbreak in Horses, Southern France, 2000: Results of a Serosurvey

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.058

Equine West Nile Encephalitis, United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.058

Outcome of equids with clinical signs of West Nile virus infection and factors associated with death

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.058

Evaluation of an outbreak of West Nile virus infection in horses: 569 cases (2002).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.058

Molecular biology of flaviviruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.058

The Relationships between West Nile and Kunjin Viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.058

Detection of antibodies to West Nile virus in equine sera using microsphere immunoassay.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.058

Incidence and effects of West Nile virus infection in vaccinated and unvaccinated horses in California.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.058

Veterinary immunology as colonial science: method and quantification in the investigation of horsesickness in South Africa, C. 1905-1945.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.058

Recombinant baculovirus-synthesized African horsesickness virus (AHSV) outer-capsid protein VP2 provides protection against virulent AHSV challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.058

The protective efficacy of a recombinant VP2-based African horsesickness subunit vaccine candidate is determined by adjuvant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.058

Immunization with VP2 is sufficient for protection against lethal challenge with African horsesickness virus Type 4.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.058

Climate change and the recent emergence of bluetongue in Europe

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.058

Emerging infectious diseases. During a hot summer, bluetongue virus invades northern Europe

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.058

VP2-segment sequence analysis of some isolates of bluetongue virus recovered in the Mediterranean basin during the 1998-2003 outbreak

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.058

Recombinant canarypox virus vaccine co-expressing genes encoding the VP2 and VP5 outer capsid proteins of bluetongue virus induces high level protection in sheep

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.058

The two major envelope proteins of equine arteritis virus associate into disulfide-linked heterodimers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.058

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2006.12.058

1 reference

15 August 2017

1 reference